Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vidutolimod (CMP-001)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Kuros, Regeneron, Xoma

Drug class:

Immunomodulator, TLR9 agonist

Related drugs:

hydroxychloroquine (7)

quaratusugene ozeplasmid (3)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

coprelotamab (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

›

No biomarker	Melanoma	No biomarker	Melanoma	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B	nivolumab + CMP-001 Sensitive: B - Late Trials nivolumab + CMP-001 Sensitive : B
No biomarker	Melanoma	No biomarker	Melanoma	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B	pembrolizumab + CMP-001 Sensitive: B - Late Trials pembrolizumab + CMP-001 Sensitive : B
CD8 positive	Melanoma	CD8 positive	Melanoma	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3	nivolumab + CMP-001 Sensitive: C3 – Early Trials nivolumab + CMP-001 Sensitive : C3